As per Regulation 30 of SEBI (LODR)Regulation,2015 uploading our Audited Financial Results for the Quarter and Year Ended on 31-03-2025. Kindly take the same on records.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories reported audited results for FY25 showing revenue from operations of Rs 652.77 lakhs, down about 7% from Rs 702.96 lakhs in FY24. Q4 revenue also fell to Rs 145.14 lakhs from Rs 162.94 lakhs a year earlier. Despite the revenue dip, profit after tax inched up modestly to Rs 49.66 lakhs (FY24: Rs 48.67 lakhs), with Q4 PAT rising to Rs 15.04 lakhs from Rs 13.60 lakhs. Full-year EPS stood at Rs 1.97 versus Rs 1.93. The statutory auditor (Vora & Associates) issued an unmodified (clean) opinion on the results. The board also approved the appointment of an additional director during the meeting.
Flat-to-mildly positive earnings despite a revenue dip signal some margin discipline, but the top-line contraction and a sharp swing to negative operating cash flow (Rs -145.37 lakhs vs Rs +103.47 lakhs last year) are concerns for shareholders. Short-term share price reaction may be muted given the small scale of operations.